Published in Mol Pharm on January 04, 2013
Particle replication in nonwetting templates nanoparticles with tumor selective alkyl silyl ether docetaxel prodrug reduces toxicity. Nano Lett (2014) 0.93
Amino Acid Prodrugs: An Approach to Improve the Absorption of HIV-1 Protease Inhibitor, Lopinavir. Pharmaceuticals (Basel) (2014) 0.79
Provisional in-silico biopharmaceutics classification (BCS) to guide oral drug product development. Drug Des Devel Ther (2014) 0.78
Biopharmaceutical Characterization of Nebulized Antimicrobial Agents in Rats: 5. Oseltamivir Carboxylate. Antimicrob Agents Chemother (2016) 0.75
Carrier-Mediated Prodrug Uptake to Improve the Oral Bioavailability of Polar Drugs: An Application to an Oseltamivir Analogue. J Pharm Sci (2016) 0.75
Hydrotropic Solubilization of Lipophilic Drugs for Oral Delivery: The Effects of Urea and Nicotinamide on Carbamazepine Solubility-Permeability Interplay. Front Pharmacol (2016) 0.75
In Silico Absorption Analysis of Valacyclovir in Wildtype and Pept1 Knockout Mice Following Oral Dose Escalation. Pharm Res (2017) 0.75
Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med (2005) 15.53
Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature (1993) 8.62
Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. Virology (1974) 6.53
Oseltamivir resistance--disabling our influenza defenses. N Engl J Med (2005) 4.41
Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature (2008) 3.79
Resistance of influenza viruses to neuraminidase inhibitors--a review. Antiviral Res (2000) 3.68
Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun (1991) 3.25
4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob Agents Chemother (1993) 2.92
The molecular biology of influenza virus pathogenicity. Adv Virus Res (1988) 2.90
Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Antimicrob Agents Chemother (2001) 2.46
Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr Top Microbiol Immunol (1992) 2.38
Human intestinal H+/peptide cotransporter. Cloning, functional expression, and chromosomal localization. J Biol Chem (1995) 2.32
Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. JAMA (1996) 2.30
Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase). Antimicrob Agents Chemother (1994) 2.22
Reduced sensitivity of influenza A (H5N1) to oseltamivir. Emerg Infect Dis (2007) 1.81
Resistance of influenza A virus to amantadine and rimantadine: results of one decade of surveillance. J Infect Dis (1989) 1.73
Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. Antimicrob Agents Chemother (1998) 1.72
5'-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm Res (1998) 1.66
Comparison between permeability coefficients in rat and human jejunum. Pharm Res (1996) 1.59
Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. J Pharm Sci (2000) 1.28
Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting. J Pharm Sci (2008) 1.25
Amino acid ester prodrugs of the anticancer agent gemcitabine: synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport. Mol Pharm (2005) 1.21
Identification of a human valacyclovirase: biphenyl hydrolase-like protein as valacyclovir hydrolase. J Biol Chem (2003) 1.19
The suitability of an in situ perfusion model for permeability determinations: utility for BCS class I biowaiver requests. Mol Pharm (2006) 1.16
Estimating human oral fraction dose absorbed: a correlation using rat intestinal membrane permeability for passive and carrier-mediated compounds. Pharm Res (1988) 1.15
Advances in influenza virus vaccine research. Ann N Y Acad Sci (1993) 1.07
Synthesis and anti-influenza evaluation of polyvalent sialidase inhibitors bearing 4-guanidino-Neu5Ac2en derivatives. Chem Pharm Bull (Tokyo) (2003) 1.04
Prodrugs of butyric acid. Novel derivatives possessing increased aqueous solubility and potential for treating cancer and blood diseases. Eur J Med Chem (2001) 0.99
Enhancing the intestinal membrane permeability of zanamivir: a carrier mediated prodrug approach. Mol Pharm (2011) 0.96
Mucins and mucoids in relation to influenza virus action; inhibition by purified mucoid of infection and haemagglutination with the virus strain WSE. Aust J Exp Biol Med Sci (1948) 0.96
Cefuroxime axetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs (1996) 0.93
Enhanced cancer cell growth inhibition by dipeptide prodrugs of floxuridine: increased transporter affinity and metabolic stability. Mol Pharm (2008) 0.93
Nucleoside ester prodrug substrate specificity of liver carboxylesterase. J Pharmacol Exp Ther (2005) 0.92
Overexpression of human intestinal oligopeptide transporter in mammalian cells via adenoviral transduction. Pharm Res (1998) 0.90
Cyclopropanecarboxylic acid esters as potential prodrugs with enhanced hydrolytic stability. Org Lett (2008) 0.90
Segmental-dependent membrane permeability along the intestine following oral drug administration: Evaluation of a triple single-pass intestinal perfusion (TSPIP) approach in the rat. Eur J Pharm Sci (2008) 0.89
Beta cyclodextrins enhance adenoviral-mediated gene delivery to the intestine. Pharm Res (1998) 0.89
Chemical and enzymatic stability of amino acid prodrugs containing methoxy, ethoxy and propylene glycol linkers. Mol Pharm (2009) 0.88
Cefpodoxime proxetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs (1992) 0.84
Innate recognition of bacteria by a macrophage cytosolic surveillance pathway. Proc Natl Acad Sci U S A (2002) 3.85
Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. Adv Drug Deliv Rev (2003) 3.25
Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm (2004) 2.63
Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation. J Exp Med (2006) 2.57
A specific gene expression program triggered by Gram-positive bacteria in the cytosol. Proc Natl Acad Sci U S A (2004) 2.10
A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan. Mol Pharm (2006) 2.07
A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J Clin Pharmacol (2002) 1.85
Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm Res (2002) 1.74
Polymer degradation and in vitro release of a model protein from poly(D,L-lactide-co-glycolide) nano- and microparticles. J Control Release (2003) 1.72
The use of BDDCS in classifying the permeability of marketed drugs. Pharm Res (2008) 1.57
Lessons learned from marketed and investigational prodrugs. J Med Chem (2004) 1.43
Summary workshop report: biopharmaceutics classification system--implementation challenges and extension opportunities. J Pharm Sci (2004) 1.43
Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. Pharm Res (2002) 1.37
Prediction of solubility and permeability class membership: provisional BCS classification of the world's top oral drugs. AAPS J (2009) 1.37
Accelerated macrophage apoptosis induces autoantibody formation and organ damage in systemic lupus erythematosus. J Immunol (2006) 1.28
Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm Res (2006) 1.26
Amino acid ester prodrugs of the anticancer agent gemcitabine: synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport. Mol Pharm (2005) 1.21
Identification of a human valacyclovirase: biphenyl hydrolase-like protein as valacyclovir hydrolase. J Biol Chem (2003) 1.19
Physiological parameters for oral delivery and in vitro testing. Mol Pharm (2010) 1.18
Listeriolysin O-liposome-mediated cytosolic delivery of macromolecule antigen in vivo: enhancement of antigen-specific cytotoxic T lymphocyte frequency, activity, and tumor protection. Biochim Biophys Acta (2002) 1.16
The suitability of an in situ perfusion model for permeability determinations: utility for BCS class I biowaiver requests. Mol Pharm (2006) 1.16
The BCS, BDDCS, and regulatory guidances. Pharm Res (2011) 1.11
Pharmacokinetics of an immediate release, a controlled release and a two pulse dosage form in dogs. Eur J Pharm Biopharm (2005) 1.10
Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol (2009) 1.08
A novel nucleoside prodrug-activating enzyme: substrate specificity of biphenyl hydrolase-like protein. Mol Pharm (2005) 1.04
Molecular basis of prodrug activation by human valacyclovirase, an alpha-amino acid ester hydrolase. J Biol Chem (2008) 1.04
Floxuridine amino acid ester prodrugs: enhancing Caco-2 permeability and resistance to glycosidic bond metabolism. Pharm Res (2005) 1.04
Targeted delivery to PEPT1-overexpressing cells: acidic, basic, and secondary floxuridine amino acid ester prodrugs. Mol Cancer Ther (2005) 1.03
Summary workshop report: bioequivalence, biopharmaceutics classification system, and beyond. AAPS J (2008) 1.01
Amino acid ester prodrugs of floxuridine: synthesis and effects of structure, stereochemistry, and site of esterification on the rate of hydrolysis. Pharm Res (2003) 1.00
Multiple efflux pumps are involved in the transepithelial transport of colchicine: combined effect of p-glycoprotein and multidrug resistance-associated protein 2 leads to decreased intestinal absorption throughout the entire small intestine. Drug Metab Dispos (2009) 1.00
Gene expression in the human intestine and correlation with oral valacyclovir pharmacokinetic parameters. J Pharmacol Exp Ther (2003) 0.99
High-permeability criterion for BCS classification: segmental/pH dependent permeability considerations. Mol Pharm (2010) 0.99
Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugs. Mol Pharm (2009) 0.98
Comparative gene expression profiles of intestinal transporters in mice, rats and humans. Pharmacol Res (2007) 0.98
Enhanced gene delivery using disulfide-crosslinked low molecular weight polyethylenimine with listeriolysin o-polyethylenimine disulfide conjugate. J Control Release (2008) 0.97
In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcome. Curr Opin Drug Discov Devel (2004) 0.97
Enhancing the intestinal membrane permeability of zanamivir: a carrier mediated prodrug approach. Mol Pharm (2011) 0.96
Blockade of interleukin-6 receptor suppresses the proliferation of H460 lung cancer stem cells. Int J Oncol (2012) 0.95
The solubility-permeability interplay in using cyclodextrins as pharmaceutical solubilizers: mechanistic modeling and application to progesterone. J Pharm Sci (2010) 0.95
Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine. Clin Pharmacokinet (2006) 0.95
Localization of protein kinase C epsilon to macrophage vacuoles perforated by Listeria monocytogenes cytolysin. Cell Microbiol (2007) 0.94
Differential cytosolic delivery and presentation of antigen by listeriolysin O-liposomes to macrophages and dendritic cells. Mol Pharm (2005) 0.94
Surfactant-mediated dissolution: contributions of solubility enhancement and relatively low micelle diffusivity. J Pharm Sci (2004) 0.94
Grapefruit juice and its constituents augment colchicine intestinal absorption: potential hazardous interaction and the role of p-glycoprotein. Pharm Res (2008) 0.94
Tacrolimus is a class II low-solubility high-permeability drug: the effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats. J Pharm Sci (2002) 0.93
Enhanced cancer cell growth inhibition by dipeptide prodrugs of floxuridine: increased transporter affinity and metabolic stability. Mol Pharm (2008) 0.93
Enabling the intestinal absorption of highly polar antiviral agents: ion-pair facilitated membrane permeation of zanamivir heptyl ester and guanidino oseltamivir. Mol Pharm (2010) 0.93
Stability of valacyclovir: implications for its oral bioavailability. Int J Pharm (2006) 0.92
The biowaiver extension for BCS class III drugs: the effect of dissolution rate on the bioequivalence of BCS class III immediate-release drugs predicted by computer simulation. Mol Pharm (2010) 0.92
A novel high-throughput pepT1 transporter assay differentiates between substrates and antagonists. Mol Pharm (2004) 0.92
Human jejunal permeability of cyclosporin A: influence of surfactants on P-glycoprotein efflux in Caco-2 cells. Pharm Res (2003) 0.92
Nucleoside ester prodrug substrate specificity of liver carboxylesterase. J Pharmacol Exp Ther (2005) 0.92
Enhanced absorption and growth inhibition with amino acid monoester prodrugs of floxuridine by targeting hPEPT1 transporters. Molecules (2008) 0.92
Permeability dominates in vivo intestinal absorption of P-gp substrate with high solubility and high permeability. Mol Pharm (2005) 0.91
Accounting for the solubility-permeability interplay in oral formulation development for poor water solubility drugs: the effect of PEG-400 on carbamazepine absorption. Eur J Pharm Biopharm (2012) 0.90
Mechanistic understanding of time-dependent oral absorption based on gastric motor activity in humans. Eur J Pharm Biopharm (2008) 0.90
The solubility-permeability interplay: mechanistic modeling and predictive application of the impact of micellar solubilization on intestinal permeation. Mol Pharm (2011) 0.89
Tumor cell killing enabled by listeriolysin O-liposome-mediated delivery of the protein toxin gelonin. J Biol Chem (2003) 0.89
Segmental-dependent membrane permeability along the intestine following oral drug administration: Evaluation of a triple single-pass intestinal perfusion (TSPIP) approach in the rat. Eur J Pharm Sci (2008) 0.89
Solubilization and dissolution of insoluble weak acid, ketoprofen: effects of pH combined with surfactant. Eur J Pharm Sci (2006) 0.88
Chemical and enzymatic stability of amino acid prodrugs containing methoxy, ethoxy and propylene glycol linkers. Mol Pharm (2009) 0.88
Amino acid ester prodrugs of the antiviral agent 2-bromo-5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazole as potential substrates of hPEPT1 transporter. J Med Chem (2005) 0.88
Purely in silico BCS classification: science based quality standards for the world's drugs. Mol Pharm (2013) 0.88
Feasibility studies of utilizing disk intrinsic dissolution rate to classify drugs. Int J Pharm (2004) 0.87
The solubility-permeability interplay when using cosolvents for solubilization: revising the way we use solubility-enabling formulations. Mol Pharm (2012) 0.87
Amino acid ester prodrugs of 2-bromo-5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazole enhance metabolic stability in vitro and in vivo. J Pharmacol Exp Ther (2005) 0.87
A win-win solution in oral delivery of lipophilic drugs: supersaturation via amorphous solid dispersions increases apparent solubility without sacrifice of intestinal membrane permeability. Mol Pharm (2012) 0.87
Comparison of the permeability of metoprolol and labetalol in rat, mouse, and Caco-2 cells: use as a reference standard for BCS classification. Mol Pharm (2013) 0.86
Cytosolic delivery of viral nucleoprotein by listeriolysin O-liposome induces enhanced specific cytotoxic T lymphocyte response and protective immunity. Mol Pharm (2004) 0.86
Enhancing the intestinal absorption of molecules containing the polar guanidino functionality: a double-targeted prodrug approach. J Med Chem (2010) 0.86
The fraction dose absorbed, in humans, and high jejunal human permeability relationship. Mol Pharm (2012) 0.86
Enhanced in vivo gene expression mediated by listeriolysin O incorporated anionic LPDII: Its utility in cytotoxic T lymphocyte-inducing DNA vaccine. J Control Release (2010) 0.86
Quasi-equilibrium analysis of the ion-pair mediated membrane transport of low-permeability drugs. J Control Release (2009) 0.85
MRP2 mediated drug-drug interaction: indomethacin increases sulfasalazine absorption in the small intestine, potentially decreasing its colonic targeting. Int J Pharm (2009) 0.84
Comparative gene expression of intestinal metabolizing enzymes. Biopharm Drug Dispos (2009) 0.84
Toward an in vivo dissolution methodology: a comparison of phosphate and bicarbonate buffers. Mol Pharm (2009) 0.83
The low/high BCS permeability class boundary: physicochemical comparison of metoprolol and labetalol. Mol Pharm (2014) 0.83
A fluorescent hPept1 transporter substrate for uptake screening. Pharm Res (2003) 0.83
The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport. AAPS J (2009) 0.83
Predicting the solubility-permeability interplay when using cyclodextrins in solubility-enabling formulations: model validation. Int J Pharm (2012) 0.83
Intestinal metabolism promotes regional differences in apical uptake of indinavir: coupled effect of P-glycoprotein and cytochrome P450 3A on indinavir membrane permeability in rat. J Pharmacol Exp Ther (2002) 0.83